Fungal persister cells: The basis for recalcitrant infections?
Open accessThe DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Persister cells are a small subpopulation within fungal biofilms that are highly resistant to high concentrations of antifungals and therefore most likely contribute to the resistance and recalcitrance of biofilm infections. Moreover, this subpopulation is defined as a nongrowing, phenotypic variant of wild-type cells that can survive high doses of antifungals. There are high degrees of heterogeneity and plasticity associated with biofilm formation, resulting in a strong variation in the amount of persister cells. The fraction of these cells in fungal biofilms also appear to be dependent on the type of substrate. The cells can be observed immediately after their adhesion to that substrate, which makes up the initial step of biofilm formation. Thus far, persister cells have primarily been studied in Candida spp. These fungi are the fourth most common cause of nosocomial systemic infections in the United States, with C. albicans being the most prevalent species. Remarkably, persisters exhibit characteristics of a dormant state similar to what is observed in cells deprived of glucose. This dormant state, together with attachment to a substrate, appears to provide the cells with characteristics that help them overcome the challenges with fungicidal drugs such as amphotericin B (AmB). AmB is known to induce apoptosis, and persister cells are able to cope with the increase in reactive oxygen species (ROS) by activating stress response pathways and the accumulation of high amounts of glycogen and trehalose-two known stress-protecting molecules. In this review, we discuss the molecular pathways that are involved in persister cell formation in fungal species and highlight that the eradication of persister cells could lead to a strong reduction of treatment failure in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Whereas tolerance is generally due to substantial subpopulations of cells (5-90%) that grow in drug, antifungal heteroresistance or persistence involve rare cells (generally <<1%) that transiently survive high concentrations of antifungal drugs14.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“biofilms are known to hinder the penetration of antifungal drugs and host immune effectors and also trigger the formation of Candida persister cells, leading to poor clinical outcomes [52,53].”
From Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs (2020) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is difficult to detect persisters in planktonic cells, which is different from bacteria [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One possible explanation is antifungal persistence, given its ability to survive lethal drug exposure without an increase of resistance level [12].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Fungal persisters are dormant variants of wild-type cells that are tolerant to antifungal drugs, surviving high dosage of antifungals that exceed the minimal inhibitory concentration (MIC) [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Maisonneuve, E., Castro-Camargo, M., & Gerdes, K. (2013) · Cell · doi:10.1016/j.cell.2013.07.048 · Cited by 438
RetractedIn situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178
Cited by
Items 101–140 of 140
Biofilm characterization in the maize pathogen, Fusarium verticillioidesPreprint
Peremore, C., Wingfield, B. D., Santana, Q. C., Steenkamp, E. T., & Motaung, T. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.18.517162 · Cited by 7
Using BONCAT to dissect the proteome of S. aureus persisters
Matlalcuatzi, E. D. C. G., Bakkum, T., Thomas, P. S., Hacker, S. M., Florea, B. I., Vriesendorp, B., Rozen, D. E., & van Kasteren, S. I. (2025) · mSphere · doi:10.1128/msphere.00431-25 · Cited by 2
“1a) and homopropargylglycine (Hpg), which can both be ligated using copper-catalyzed [3 + 2]-cycloaddition reactions, which is a very low-background click reaction (42, 43, 45–47).”
Shi, J., Lan, N., Zeng, F., Liu, N., Xue, C., & Yang, B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1774864 · Cited by 3
“” These are a small subpopulation of phenotypic variants within the bio fi lm that exist in a dormant, metabolically quiescent state (Wuyts et al., 2018).”
Quiceno, E., Rodríguez-Almonacid, C. C., Omeir, K., Ancira, J. S., Phillips, C. D., & Karamysheva, Z. N. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014682 · Cited by 2
“Persisters are known to be present in bacteria [8], fungal pathogens [9] and protozoa parasites [10].”
Karácsony, Z., Molnár, N., Szabó, D., Bakos-Barczi, N., Lovas, M., Pálfi, X., & Váczy, K. Z. (2024) · Mycological Progress · doi:10.1007/s11557-024-01976-y · Cited by 2
“…proposes several advantages for this pathogen by decreasing the effectiveness of antimicrobial compounds (Silva et al. 2017), and as a multicellular structure, allowing the specialization of cells to different functions like persistence (Wuyts et al. 2018), or dispersion (Uppuluri et al. 2018).”
The Xiangya Lesion: A Paradigm Shift in Understanding Fungal Pathogenesis
Xiujuan, Y., & Zhu, X. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005909 · Cited by 2
Biofilm Formation in Candida Species
Elibe, M. I., & Innocent, N. E. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_9 · Cited by 2
Nicoletti, G., & White, K. S. (2022) · Antibiotics · doi:10.3390/antibiotics11091188 · Cited by 2
Cellular and material-specific responses of Candida parapsilosis biofilms to biocides
Dourado, J. K. D. S., Alvarez, C., Benard, G., & Pires, R. H. (2025) · Journal of Hospital Infection · doi:10.1016/j.jhin.2025.04.023 · Cited by 2
Ramage, G., Kean, R., Mackay, W. G., Vaccaro, A., Lopez-Ribot, J. L., & Howe, M. H. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_7 · Cited by 2
Comparative Genomics in Understanding Microbial Biofilms
Swamy, P. R., & Sharma, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-91863-6_11 · Cited by 1
Cytrynbaum, E. G., & McClean, M. N. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115740 · Cited by 1
Chimeric Antigen Receptor (CAR)-based and Other Novel Immunotherapies for Invasive Candidiasis
Guimarães, J. G., Carvalho, S. L., Marangoni, M. E. D., Lee, C., da Silva, T. A., & de Campos, G. Y. (2025) · Infectious diseases · doi:10.5772/intechopen.1013127 · Cited by 1
Liu, R., Yao, L., Hu, Q., Chen, Z. Y., Xu, B., Cao, L., & Mu, W. (2026) · Bone and Joint Research · doi:10.1302/2046-3758.155.bjr-2025-0459.r2 · Cited by 1
“13,20 In parallel, physiological stratifcation generates reservoirs of “persister cells”, 21 while extracellular vesicles (EVs) enhance bioflm resilience.”
Navigating the Third Frontier of Antimicrobial Therapy to Support Women’s Health
Wittman, E., Yar, N., & Larsen, B. (2020) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2020.1080096 · Cited by 1
Al-Ameri, H. A. (2021) · Mağallaẗ al-tarbiyaẗ wa-al-ʻilm · doi:10.33899/edusj.2021.168652 · Cited by 1
Singla, M., Chaudhary, V., & Ghosh, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-3120-7_2 · Cited by 2
Tasleem, Shanthi, N., Mahato, A. K., & Bahuguna, R. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103808 · Cited by 1
Management of Fungal Osteoarticular Infections
Henry, M. W., & Miller, A. O. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00453-5 · Cited by 1
de Andrade, A. R. C., Rezende, M. D. S., Portela, F. V. M., Pereira, L. M. G., da Silva, B. N., de Lima-Neto, R. G., Rocha, M. F. G., Sidrim, J. J. C., Castelo‐Branco, D. D. S. C. M., & Cordeiro, R. D. A. (2023) · Biofouling · doi:10.1080/08927014.2023.2256674 · Cited by 1
“glabrata biofilms have low competence in producing PC (Al-Dhaheri and Douglas 2008; Wuyts et al. 2018), our data showed that C.”
"Adaptive mutations" in the S/MAPK pathways provide selective advantage in quiescent fission yeast
Makarenko, R. (2019) · theses.fr (ABES) · doi:10.70675/bba26e61z22aaz4e54zb761zcc77108b0efa
Dumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., et al. (2023) · eLife · doi:10.7554/elife.81406.sa2
Portela, F. V. M., de Andrade, A. R. C., Pereira, L. M. G., da Silva, B. N., Peixoto, P. H. S., Amando, B. R., Fiallos, N. D. M., de Souza, P. D. F. S. M., de Lima-Neto, R. G., Guedes, G. M. D. M., et al. (2024) · Biofouling · doi:10.1080/08927014.2024.2396013
“It is believed that PCs contribute to the pathogenesis of several biofilm-associated infections, contributing to prolonged treatment and increasing the risk of refractory infections in immunocompromised patients (Bojsen et al. 2014; Wuyts et al. 2018; Wainwright et al. 2021).”
InfluentialHsiao, K.-C., Lin, H.-Y., Hazbun, T. R., & Kuo, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618937
Wang, Y., Ye, S., Deng, Y., Huang, Y., & Zhu, X. (2025) · Research Square · doi:10.21203/rs.3.rs-5862334/v1
RetractedWang, Y., Ye, S., Deng, Y., Huang, Y., & Zhu, X. (2025) · Research Square · doi:10.21203/rs.3.rs-5862334/v2
RetractedProteomics and its Applications in Biofilm Research
Ahmed, Z. H. T., Singh, P., Haque, M. R., Vasudevan, D., Rajesh, V., Ravichandran, S. S., Srinivasan, D., Maqbool, M., & Hassan, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-91863-6_6
Dormant yet dangerous: the role of cell rest in perseverance
Bocca, A. L., Trindade, G. B., Souza, R. L., & Fernandes, L. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2599700
“These approaches could open new perspectives in the treatment of infections caused by C. neoformans and in the management of fungal dormancy [29,89] Further studies are needed to identify these targets that could contribute to novel fungal therapeutic strategies or the improvement of existing ones.”
de Andrade, A. R. C. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Development of in vivo models to study candida infections and innate immune responses
Rogiers, O. (2022) · Lirias
Feyaerts, A. F. (2019) · Lirias (KU Leuven)
Environmental adaptation of Candida albicans : the examples of persistence and chlamydosporulation
Denega, I. (2020) · theses.fr (ABES) · doi:10.70675/748584ddzf6f4z4124z9237z56d0535d3352
Functional and structural studies of drug efflux by Cdr1p, an ABC transporter of Candida fungi
Pata, J. (2023) · theses.fr (ABES) · doi:10.70675/6adbc74dzad88z4878zbfc2z4a16da9e0458
David, H., Balu, P. S., Vasudevan, S., Narayanan, V. H. B., Solomon, A. P., & Ramyadevi, D. (2026) · Scientific Reports · doi:10.1038/s41598-026-52764-5
“…potential of C. albicans to transition from yeast to hyphal cells and create structured biofilms further complicates the ability to treat, as biofilms provide a physical barrier to drug permeation and have persister cells that exhibit phenotypic resistance, irrespective of genetic mutations 35–38 .”
Prevalence and phenotypic features of voriconazole persistence in Aspergillus fumigatus
Li, X., Zhou, Z., Lin, H., Guo, J., Wu, W., Goldman, G. H., Lu, L., & Zhang, Y. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2679240
Pimenta, G. R., Gualque, M. W. D. L., Siqueto, M. J., Silva, S. D. M., Regasini, L. O., Mendes‐Giannini, M. J. S., & Fusco‐Almeida, A. M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00203-26
“One indication supporting this hypothesis is that energy availability (ATP) is stored as a reserve in these cells during stress, allowing them to resume proliferation under favorable conditions later (9, 27).”
InfluentialMonari, G. P. D. M., Coelho, A. A. D. F., de Sousa, D. S. M., Berretta, A. A., de Lima, J. A., Paula, C. R., da Rosa, C. F., dos Santos, F. S. M., Nogueira, M. R. S., Auler, M. E., et al. (2026) · Fitoterapia · doi:10.1016/j.fitote.2026.107412
Garcia, M. T., Bautista, E., Vázquez, S., Pons, R., Morán, M. C., & Pérez, L. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.116220
Metadata
- Authors
- Wuyts, J., Van Dijck, P., & Holtappels, M.
- Affiliations
- VIB-KU Leuven Center for Microbiology (BE)
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-18
- Volume
- 14
- Issue
- 10
- Pages
- e1007301
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6193731
- OpenAlex
- W2897950718
- Cited by
- 136
- References
- 87
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 19 · 2020: 19 · 2019: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Belgian Federal Science Policy Office
- KU Leuven (C14/17/063)
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- fungal biofilms, antifungal resistance, recalcitrant infection, Candida albicans, Candida, amphotericin B resistance, dormancy, reactive oxygen species, stress response pathways, trehalose, glycogen, nosocomial fungal infections, treatment failure
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Cross Infection, Humans, Biofilms, Drug Resistance, Multiple, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.